The Brookbush Institute continues to enhance education with new articles, new courses, a modern glossary, an AI Tutor, ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Japan approves world-first iPS cell therapies for heart failure, Parkinsons Conditional approvals speed Japans first iPS treatments into clinics for heart failure and Parkinsons ...

For a heart just damaged by a blocked artery, timing matters. So does access. That is what makes a new experimental treatment ...

"Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD," said Michael Amoroso, Chief Executive Officer of Precision BioSciences. "We ...

A conserved glucagon signaling pathway links high-fat diet-induced metabolic imbalance to cardiac arrhythmia through hormone-producing cells and heart-innervating neurons that regulate rhythmicity.

The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory ...

This important study advances our understanding of developmental timing mechanisms by studying the cleavage, nuclear translocation, and oscillation of the transcription factor MYRF-1 (vertebrate MYRF) ...

Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional ...

ITF Therapeutics LLC, the U.S. rare disease affiliate of Italfarmaco, today announced the presentation of ten abstracts at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference ...